: AMPK controls muscle cell size by Lantier, Louise et al.
Coordinated maintenance of muscle cell size control by
AMP-activated protein kinase.
Louise Lantier, Re´mi Mounier, Jocelyne Leclerc, Mario Pende, Marc Foretz,
Benoit Viollet
To cite this version:
Louise Lantier, Re´mi Mounier, Jocelyne Leclerc, Mario Pende, Marc Foretz, et al.. Coor-
dinated maintenance of muscle cell size control by AMP-activated protein kinase.. FASEB
Journal, Federation of American Society of Experimental Biology, 2010, 24 (9), pp.3555-61.
<10.1096/fj.10-155994>. <inserm-00484177>
HAL Id: inserm-00484177
http://www.hal.inserm.fr/inserm-00484177
Submitted on 18 May 2010
HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.
L’archive ouverte pluridisciplinaire HAL, est
destine´e au de´poˆt et a` la diffusion de documents
scientifiques de niveau recherche, publie´s ou non,
e´manant des e´tablissements d’enseignement et de
recherche franc¸ais ou e´trangers, des laboratoires
publics ou prive´s.
Coordinated maintenance of muscle cell size control by 
AMP-activated protein kinase 
 
 
Louise Lantiera,b*, Rémi Mouniera,b*, Jocelyne Leclerca,b, Mario Pendec,d, Marc Foretza,b, and 
Benoit Violleta,b,1 
 
 
Affiliations: 
aInstitut Cochin, Université Paris Descartes, CNRS (UMR 8104), Paris, France; bINSERM 
U1016, Paris, France, cINSERM, U845, Paris, France; dUniversité Paris Descartes, UMRS-
845, Paris, France. 
*These authors have equally contributed to this work 
 
 
Running Title: AMPK controls muscle cell size  
 
 
1To whom correspondence may be addressed: 
Benoit Viollet, INSERM U1016, Institut Cochin, Département Endocrinologie, Métabolisme 
et Cancer, 24, rue du Faubourg Saint-Jacques, 75014 Paris, France. 
Email: benoit.viollet@inserm.fr 
Abstract 
Skeletal muscle mass is regulated by signaling pathways that govern protein synthesis and 
cell proliferation, the mammalian target of rapamycin (mTOR) playing a key role in these 
processes. Recent studies suggested the crucial role of AMP-activated protein kinase (AMPK) 
in the inhibition of protein synthesis and cell growth. Here, we address the role of AMPK in 
the regulation of muscle cell size in vitro and in vivo. The size of AMPK-deficient myotubes 
was 1.5-fold higher than for controls. A marked increase in p70S6K Thr389 and rpS6 Ser235/236 
phosphorylation was observed concomitantly with an up-regulation of protein synthesis rate. 
Treatment with rapamycin prevented both p70S6K phosphorylation and rescued cell size 
control in AMPK-deficient cells. Furthermore, myotubes lacking AMPK were resistant to 
further cell size increase beyond AMPK deletion alone, as MyrAkt-induced hypertrophy was 
absent in these cells. Moreover, in skeletal muscle-specific deficient AMPKα1/α2 KO mice, 
soleus muscle showed a higher mass with myofibers of larger size and was associated with 
increased p70S6K and rpS6 phosphorylation. Our results uncover the role of AMPK in the 
maintenance of muscle cell size control and highlight the crosstalk between AMPK and 
mTOR/p70S6K signaling pathways coordinating a metabolic checkpoint on cell growth. 
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Introduction 
Regulation of muscle mass depends on a thin balance between growth promoting and growth 
suppressing factors. Alterations in skeletal muscle mass are controlled by the regulation of 
complex cell signaling pathways that govern muscle protein synthesis, breakdown and cell 
proliferation.  
Signaling through the mammalian target of rapamycin (mTOR) plays a key role in cell growth 
regulation and particularly in the control of protein synthesis (1). The activation of mTOR by 
the GTPases rheb and rag and the sequential activation of its downstream targets enhances 
mRNA translation, initiation and elongation, resulting in an increase of muscle protein 
synthesis and growth (2). mTOR is part of two distinct multiprotein complexes: mTORC1 
and mTORC2. The mTORC1 complex (containing mTOR, mLST8/GβL, PRAS40 and 
raptor) is responsible for cell growth. It is rapamycin sensitive and is activated by amino 
acids, hormones/growth factors and energy signals (2). In contrast, the mTORC2 complex 
(containing mTOR, mLST8 and rictor) is important in the organization of actin cytoskeleton 
(3). There is clear evidence that signaling through mTOR is required for muscle hypertrophy 
(4, 5) and this process is mediated in part via activation of skeletal muscle p70S6K (6, 7). 
Phosphorylation of p70S6K is associated with increased muscle mass following hypertrophic 
stimuli, whereas muscle atrophy is associated with reduced p70S6K phosphorylation and an 
overall decrease in protein abundance (4).  
A number of recent studies have revealed the key role of AMP-activated protein kinase 
(AMPK) in the inhibition of protein synthesis by suppressing the function of multiple 
translation regulators of the mTORC1 signaling complex in response to cellular energy 
depletion and low metabolic conditions (8, 9). AMPK is an evolutionary conserved 
serine/threonine kinase that regulates energy homeostasis and metabolic stress (10). AMPK is 
a heterotrimeric complex, consisting of a catalytic α-subunit and the regulatory β- and γ-
subunits, which functions as a fuel sensor to coordinate the balance between energy 
consuming and energy producing processes. When the cellular AMP/ATP ratio is high, 
AMPK is activated, switching off ATP-consuming anabolic pathways and switching on ATP-
producing catabolic pathways. This would typically occur when AMPK is activated as a 
result of energy deprivation, the net result being suppression of protein synthesis and cell 
growth. AMPK could therefore modulate skeletal muscle mass and limit overloading-induced 
muscle hypertrophy (11-13). Several lines of evidence suggest that AMPK reduces both the 
initiation and the elongation of ribosomal peptide synthesis (14-16). One mechanism is linked 
to the ability of AMPK to effectively suppress mTORC1 signaling (17). AMPK directly 
phosphorylates the TSC2 tumour suppressor (9), mTOR (18) as well as the critical mTORC1 
binding subunit raptor  to induce rapid suppression of mTORC1 activity. 
While AMPK activation is emerging as a powerful way to suppress protein synthesis through 
the downregulation of mTOR signaling in skeletal muscle (17, 19, 20), the regulation of these 
signaling pathways has not been studied in muscle cells lacking AMPK. Therefore, the aims 
of the present study were to define whether the deletion of AMPK catalytic subunits affects 
muscle cell size control in unstimulated as well as in response to hypertrophic stimuli. We 
tested the hypothesis that AMPK deletion would result in enhanced activation of signaling 
pathways that promote protein synthesis and cell hypertrophy. Herein, we found that AMPK-
deficient myotubes have a greater cell size, a marked increase in p70S6K Thr389 and rpS6 
Ser235/236 phosphorylation, and an enhanced protein synthesis rate. Following transfection 
with an adenovirus expressing MyrAkt, an effector known to enhance protein synthesis 
through activation of the mTOR pathway, we have observed an increase in Wild Type (WT) 
myotube size while there was no difference in AMPK-deficient myotubes. Furthermore, we 
report that soleus muscle from skeletal muscle AMPK-deficient mice showed a shift of fiber 
size distribution toward higher values correlated with increased p70S6K Thr389 and rpS6 
Ser235/236 phosphorylation. Our findings highlight the crosstalk between AMPK and 
mTOR/p70S6K signaling pathway in the adaptative response of skeletal muscle for the 
control of muscle cell size. 
 
Material and methods 
Animals 
To obtain skeletal muscle AMPK-deficient mice (AMPKα1-/-α2fl/fl HSA-Cre+ mice), 
AMPKα1-/-α2fl/fl mice (21, 22) were interbred with transgenic mice expressing the Cre 
recombinase under the control of the human skeletal actin (HSA) promoter, which is 
expressed in differentiated multinucleated skeletal fibers (23). Animals were maintained on a 
12h:12h light-dark cycle and received standard rodent chow and water ad libitum. All 
procedures were performed in accordance with the principles and guidelines established by 
the European Convention for the Protection of Laboratory Animals. Animal studies described 
herein were reviewed and approved (agreement no. 75-886) by the Directeur Départemental 
des Services Vétérinaires of the Préfecture de Police de Paris. 
Cell cultures, adenovirus infection and immunostaining 
Primary muscle cell cultures were derived from mice as described previously (13). WT and 
AMPKα1-/-α2fl/fl myoblasts were infected with either GFP or Cre adenovirus at the 
multiplicity of infection (m.o.i.) of 50. After 24h, myoblasts were submitted to a second round 
of infection in the same conditions. Diameter of myotubes was measured after four days of 
differentiation using Metamorph software (Molecular Devices) as previously described (13). 
Diameter of myotubes was measured in a region where myonuclei were absent and diameter 
was constant. For immunostaining, myotubes were fixed with 4% formaldehyde, 
permeabilized with Triton X-100 and exposed to P-rpS6 (Ser235/236) antibody (Cell Signaling 
Technology).  
Tissue collection 
Animals were anaesthetized with xylazine-ketamine and soleus muscles of both legs were 
removed, cleaned and precisely weighed. Muscles were then frozen in liquid nitrogen for 
protein extraction or in liquid nitrogen-chilled isopentane for preservation of fiber 
morphology and stored at -80°C until processed. The fiber cross-sectional area of soleus 
muscle was determined by staining serial transverse sections (12-16 μm thick) with mouse 
anti-dystrophin Dys2 antibody (Novocastra) as previously described (13). 
Protein isolation and immunoblotting 
Total protein from soleus muscles and myotubes were extracted as described previously (13) 
and subjected to immunoblot. Blots were probed with antibodies against total AMPKα1, 
AMPKα2 (a kind gift from G. Hardie), b-actin (Sigma), phosphorylated and total forms of 
AMPK (Thr172), ACC (Ser79), raptor (Ser792), rpS6 (Ser235/236) and p70S6K (Thr389) (Cell 
Signaling Technology). 
Protein synthesis measurements 
After 4 days of differentiation, myotubes were serum-starved for two hours and then exposed 
to rapamycin (30mM, 1h). Protein synthesis rate was then measured as previously described 
by incorporation of 35S-Methionine and 35S-Cysteine (EasyTag Express Protein Labelling 
mix, Perkin Elmer, Waltham, MA, USA). (16). Identical incubations were conducted on 
parallel plates that contained no cells for blanks measurement.  
Statistical analysis  
Results are expressed as means ± SEM. We used Student’s t test for unpaired data. 
Differences were considered significant if P < 0.05. 
 
Results 
Generation of myotubes lacking both AMPKα1 and α2 catalytic subunits 
In undifferentiated WT myoblasts, only a low AMPKα1 subunit expression was noticeable 
whereas AMPKα2 subunit was not detected (Figure 1A). However, as differentiation 
progresses, levels of both AMPKα1 and α2 catalytic subunits gradually increased, reaching a 
maximum by day 4 (Figure 1A). In AMPKα1-/-AMPKα2fl/fl myotubes, AMPKα1 subunit was 
absent in both undifferentiated myoblasts and differentiated myotubes, whereas AMPKα2 
subunit expression levels showed an increase during differentiation without any significant 
difference with WT myotubes (Figure 1A). To obtain myotubes lacking both AMPKα1 and 
AMPKα2 catalytic subunits, we infected primary AMPKα1-/-AMPKα2fl/fl myoblasts with 
Cre-expressing adenovirus (Ad-Cre). Myoblasts were infected with GFP-expressing 
adenovirus as a control. Expression of Cre resulted in the loss of AMPKα2 protein during the 
differentiation process and AMPKα2 protein was absent after 4 days of differentiation 
(Figure 1B). Additionally, AMPKα1 protein expression was undetectable in Ad-Cre-infected 
myoblasts and 4 days after initiation of differentiation (Figure 1B). AMPK-deficient 
myoblasts efficiently initiate the differentiation program, as evidenced by the typical up-
regulation of myogenin expression after 1 day of differentiation to about equal levels in both 
WT and AMPK-deleted cells (data not shown). AMPK-deficient myotubes were fully 
differentiated at day 4 as assessed by morphology (Figure 2A). 
Lack of ACC and raptor phosphorylation following AICAR, metformin and A-762669 
treatment in AMPK-deficient myotubes 
Myotubes lacking both expression of AMPKα1 and α2 catalytic subunits (referred to as 
AMPKα1-/-α2-/-) were treated with the AMPK activators AICAR (5-aminoimidazole-4-
carboxamide-1-β-D-ribofuranoside) (24), metformin (25) and A-762669 (26). 
Phosphorylation of AMPK at Thr172 was increased in response to AMPK activators in WT 
myotubes but was undetectable in AMPK-deficient myotubes (Figure 1C). The effect of 
AMPK activators on ACC phosphorylation was abolished in AMPKα1-/-α2-/- myotubes 
confirming that induction of ACC phosphorylation by AICAR, metformin and A-762669 is 
completety dependent on AMPK activation in muscle cells. We also examined 
phosphorylation of raptor, a recently identified AMPK target in the regulation of protein 
synthesis pathway (8). Raptor is phosphorylated at Ser792 following AICAR, metformin and 
A-762669 treatment in WT but not in AMPKα1-/-α2-/- myotubes, precisely paralleling ACC 
phosphorylation pattern (Figure 1C). 
Regulation of muscle cell size in the absence of AMPK 
To determine whether AMPK contributes to the control of muscle cell size, we measured the 
effect of AMPK deletion on myotube size at differentiation day 4 (Figure 2A). The size of 
AMPKα1-/-α2-/- myotubes was 1.5-fold greater than for WT myotubes (Figure 2B). 
Accordingly, the distribution of AMPKα1-/-α2-/- myotubes size showed higher number of 
large cells and a smaller proportion of small cells (Figure 2C). Myoblasts fusion was similar 
in WT and AMPKα1-/-α2-/- muscle cultures indicating that cell hypertrophy promoted in the 
absence of AMPK is due to enhanced cytoplasmic growth rather than increased myoblasts 
fusion (data not shown). 
To address whether inactivation of AMPK signaling was sufficient to upregulate the mTOR 
pathway, we measured the phosphorylation of p70S6K as surrogate marker of mTOR kinase 
activity. Interestingly, deletion of AMPK results in a rise in p70S6K phosphorylation at Thr389 
and of its downstream target ribosomal protein S6 at Ser235/236 as assessed by Western blot 
and immunofluorescence analysis (Figures 3A and 3B). Interestingly, the protein quantity 
recovered per well was twice as high in AMPKα1-/-α2-/- myotubes compared to WT myotubes 
(Figure 3C). The rate of protein synthesis measured by 35S-methionine incorporation was 
increased 2-fold in AMPKα1-/-α2-/- myotubes (Figure 3D) compared to WT myotubes. The 
protein synthesis rate was sensitive to rapamycin in both WT and AMPKα1-/-α2-/- myotubes, 
as it was decreased by half after rapamycin treatment (30μM, 1h), decreasing the protein 
synthesis rate in AMPK-deficient myotubes to the level of WT myotubes in basal conditions 
(Figure 3D). Accordingly, treatment with rapamycin abolished phosphorylation of p70S6K at 
Thr389 in both WT and AMPKα1-/-α2-/- myotubes (Figure 3E). We therefore wished to 
investigate the effect of rapamycin on cell size and mTOR downstream components leading to 
the stimulation of skeletal muscle protein synthesis in AMPKα1-/-α2-/- myotubes. This mTOR 
pathway blunting significantly affected the size of both WT and AMPKα1-/-α2-/- myotubes, 
decreasing the myotube diameter of AMPK-deficient cells to the level of WT cells (Figures 
2A, B and C). 
MyrAkt-induced cell hypertrophy in WT but not in AMPKα1-/-α2-/- myotubes 
To investigate the functional consequence of AMPK deletion on mTOR-mediated 
hypertrophy, WT and AMPKα1-/-α2-/- muscle cells were infected with an adenovirus 
expressing constitutive active Akt (MyrAkt). The diameter of myotubes increased by 20% in 
WT cells whereas it was not affected in AMPKα1-/-α2-/- myotubes (Figures 4A and B). In 
addition, we measured the phosphorylation of p70S6K as surrogate marker of mTOR kinase 
activity. We observed a significant increase in p70S6K phosphorylation only in WT myotubes 
introduced with MyrAkt, consistent with an absence of negative action of AMPK on 
mTOR/p70S6K signaling pathway in response to hypertrophy in AMPKα1-/-α2-/- myotubes 
(Figure 4C).  
Increased muscle fiber size in skeletal muscle AMPK-deficient mice 
To extend our findings in vivo, AMPKα1-/-α2fl/fl mice were interbred with transgenic mice 
expressing the Cre recombinase under the control of the human skeletal actin (HSA) 
promoter, which is exclusively expressed in differentiated multinucleated skeletal fibers (23). 
The resulting skeletal muscle AMPK-deficient mice were viable and appeared normal in all 
respects as compared to HSA-Cre transgenic controls. The body weight of AMPKα1-/-α2fl/fl 
HSA-Cre+ mice was similar with that of control mice (data not shown). Skeletal muscle-
specific deletion of AMPKα2 was examined by western blot analysis. AMPKα2 expression 
was undetectable in soleus muscle from muscle AMPK-deficient mice (Figure 5A), with no 
sign of deletion in liver and heart (data not shown). Additionally, AMPKα1 was also absent 
in soleus muscle from muscle AMPK-deficient mice (Figure 5A). To determine whether 
AMPK deletion affects skeletal muscle mass, we compared the soleus muscle weight from 
AMPKα1-/-α2fl/fl HSA-Cre+ and HSA-Cre- mice. Soleus muscle mass was significantly higher 
by 42% in muscle AMPK-deficient mice compared to control mice (Figure 5B). Histological 
analysis of AMPK-deficient soleus muscle revealed increased cross-sectional area of the 
fibers (Figure 5C). Furthermore, myofiber size distribution of AMPK-deficient soleus muscle 
exhibits increased number of large myofibers and fewer small myofibers compared to control 
soleus muscle (Figures 5D). Finally, fiber hypertrophy in AMPK-deficient soleus muscle was 
associated with increased phosphorylation of p70S6K at Thr389 (Figure 5A) and of its 
downstream target ribosomal protein S6 at Ser235/236 (Figure 5A). 
 
Discussion 
The mTORC1 signaling pathway has recently emerged as a crucial point of convergence for 
signaling by nutrients (glucose, amino acids), growth factors and cellular energy to promote 
skeletal muscle growth and fiber size (2, 4, 5, 7). As opposed to the mTORC1 signaling 
pathway, AMPK is activated under conditions of energy stress leading to high intracellular 
AMP/ATP ratio and restores cellular energy balance by promoting ATP-generating pathways, 
while simultaneously inhibiting ATP-utilizing pathways (10). Cell growth is energetically 
demanding and its inhibition is therefore an important mechanism to save energy under 
metabolic stress. To suppress mTOR signaling, AMPK utilizes both direct and indirect targets 
via phosphorylation and activation of TSC2 on Thr1227 and Ser1345 (9), and/or phosphorylation 
and inactivation of mTOR on Thr2446 (18). AMPK has also recently been shown to inhibit 
mTORC1 directly, via phosphorylation of raptor on Ser722/Ser792 (8). Here, we confirmed that 
raptor is rapidly phosphorylated in muscle cells treated with AMPK activators but induction 
of its phosphorylation was lost in muscle cells deleted for both AMPK catalytic subunits 
(Figure 1C), indicating an AMPK-dependent effect.  
Recent evidence indicates that AMPK acts as a cellular energy checkpoint to prevent cell 
growth when cellular energy reserves are insufficient (8, 27). Hence, AMPK inhibits protein 
synthesis when nutrient conditions are limited by interfering with anabolic signaling mediated 
by the mTOR pathway. Our results provide strong evidence for the crucial role of AMPK in 
the maintenance of cell size through the control of mTOR/p70S6K signaling pathway. 
Deletion of AMPK in muscle cells enhanced p70S6K phosphorylation and in turn, protein 
synthesis rate, contributing to the shift in muscle cell and fiber size distribution toward high 
values (Figure 2C, 3A and 3D). Interestingly, treatment of AMPK-deficient cells with 
rapamycin completely blocked the up-regulation of p70S6K phosphorylation and rescued 
AMPKα1-/-α2-/- muscle cell size (Figure 2C and 3E). Consistent with our results, analysis of 
signaling downstream of mTORC1 has revealed the contribution of p70S6K phosphorylation 
in the control of muscle cell size and muscle hypertrophy (7). Muscle cells lacking p70S6K 
exhibited reduced cell size and failed to adapt their size to the inhibitory effect of rapamycin 
or amino acid starvation (7). Suppression of p70S6K signaling triggers an energy stress 
response defined by an increase in the AMP/ATP ratio leading to the activation of AMPK (6). 
This increase in AMPK activity blunts the growth responses to nutrient availability and 
inhibits signals that affect the regulation of muscle size. In this context, AMPK inhibition 
restores muscle cell growth and sensitivity to nutrient signals (6). Of note, inactivation of 
mTORC1 has previously been demonstrated to be critical for the ability of AMPK to integrate 
energy sensing with cell growth and proliferation requirement (9, 28). In contrast, loss of 
AMPK induces an absence of p70S6K inhibition, leading to higher protein synthesis rate and 
ultimately to increased muscle cell size. Interestingly, AMPKα1-/-α2-/- myotubes are resistant 
to MyrAkt hypertrophic action (Figure 4A and 4B) and p70S6K phosphorylation was not 
further increased in the absence of AMPK suggesting a ceiling effect (Figure 4C). One 
possible explanation is that mTOR signaling pathway is already activated at its maximal level 
in the absence of AMPK and no further increase is possible in response to Akt stimulation. 
Furthermore, it is possible that AMPK deletion also limits energy production for cell growth 
in response to MyrAkt-induced hypertrophy. Impaired mitochondrial function has been 
demonstrated in skeletal muscle of mice expressing a kinase-dead AMPKα2 subunit in 
skeletal muscle (29). Accordingly, impaired ATP generation was observed in skeletal muscle 
of these mice following chronic energy deprivation (30) and exercise (29). In addition, a 
marked energy disturbances was also reported during exercise in skeletal muscle of AMPK
2-/- mice (31) supporting the role of AMPKα2 in metabolic adaptations of skeletal muscle 
(32). These observations are completely consistent with the model that AMPK plays an 
essential role in the coordination between cell growth and cellular energy levels. 
The inability of AMPK-deficient muscle cells to sense the cellular energy status triggers a 
signal equivalent to high energy content and a nutrient-rich environment, leading to the 
hypertrophy of AMPKα1-/-α2-/- myotubes. These results show the major impact of AMPK 
deletion on muscle cell size in our model. The physiological relevance of these data has been 
investigated in our skeletal muscle AMPK-deficient mice model. Interestingly, the increase in 
muscle mass and fiber size found in the soleus muscle is associated with an activation of the 
p70S6K/mTOR pathway (Figure 5). These findings demonstrate that in vivo as well as in 
vitro, AMPK is highly implicated in the maintenance of muscle cell size. Thus, a crosstalk 
between p70S6K and AMPK establishes a thin balance integrating cellular energy and 
nutrition content, and leading to changes in growth and metabolic rates. Evidence is 
accumulating that the molecular interplay between AMPK and mTOR signaling also limit 
hypertrophy in the heart to various stimuli. Treatment of neonatal rat cardiomyocytes with 
metformin, AICAR or resveratrol activated AMPK and inhibited the development of 
hypertrophy during phenylephrine treatment (33, 34). Notably, increased heart hypertrophy 
was observed in AMPKα2-deficient mice following isoproterenol treatment (35) or transverse 
aortic constriction (36), which correlated with dramatic increases in mTORC1 signaling. 
Recent studies have also linked AMPK and protein degradation in the muscle. Indeed, 
AICAR and metformin treatments decreased protein synthesis and increased protein 
degradation in an AMPK-dependant manner in C2C12 myotubes (37). Another study, also in 
C2C12 myotubes, has shown that AMPK activation stimulates myofibrillar protein 
degradation by increasing FOXO transcription factors (38). In our AMPK-deficient models, 
protein degradation may well be downregulated, thus emphasizing the observed phenotype. 
The increased protein quantity and associated hypertrophy observed may result from both an 
increase in protein synthesis and a decrease in protein degradation. 
AMPK has emerged over the last decade as a central integrator of signals that control energy 
balance. Our results extend this notion by showing that AMPK controls muscle cell size and 
is involved in the cell size maintenance through the regulation of mTOR/p70S6K pathway. 
The recent findings that mTORC1 regulates muscle insulin signaling (39) and metabolism 
(40) in addition to protein synthesis suggest that AMPK metabolic effects might be mediated, 
at least in part, through modulation of mTORC1 activity. Thus, our data support the view that 
crosstalk between of AMPK and mTOR/p70S6K defines a metabolic program coordinating 
muscle plasticity. 
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Figure Legends 
 
Figure 1: Generation of AMPKα1-/-α2-/- myotubes  
AICAR, metformin and A-769662-induced AMPK and ACC phosphorylation in muscle 
cells. (A) AMPKα1 and α2 expression in WT and AMPKα1-/-α2fl/fl myotubes during 
differentiation. Myoblasts were differentiated and proteins were harvested every 24 hours 
during 6 days of differentiation. (B) Myoblasts were twice subjected to AdGFP or AdCre 
infection (50 m.o.i.). Twenty four hours after the second infection, myoblasts were split and 
differentiated in myotubes. Cells were harvested on day 4 of differentiation and proteins were 
subjected to an α1 or α2 immunoblotting. (C) Western blot of P-AMPK, AMPK, P-ACC, 
ACC, P-raptor, raptor and β-actin on myotubes incubated with AICAR (500μM, 5 hours), 
metformin (500μM, 5 hours) or A-769662 (10 or 50μM, 2h). 
Figure 2: Cell size control in muscle cells lacking AMPK. (A and B) Cells on day 2 of 
differentiation were treated with 20 nM rapamycin or vehicle. After another 2 days, bright-
field images were taken and myotube size was measured and expressed as percentage of WT 
muscle cells. (C) Frequency distribution of size of WT and AMPKα1-/-α2-/- myotubes. 
Results are represented as means ± SEM. Different from untreated cells of the same genotype: 
#P<0.05; different for the same conditions of treatment: **P<0.01. 
Figure 3: Upregulation of mTOR signaling pathway in AMPKα1-/-α2-/- myotubes. (A) 
Western blot of AMPKα1, AMPKα2, P-p70S6K, p70S6K, P-rpS6 and rpS6 in myotubes at 
day 4 of differentiation. (B) Immunostaining for P-rpS6 in WT and AMPKα1-/-α2-/- 
myotubes. (C) Protein quantity was measured in WT and α1-/-α2-/- myotubes after 4 days of 
differentiation from wells seeded at the same density. (D) Protein synthesis rate as measured 
before and after treatment with rapamycin (30μM, 1h) (E) Western blot of P-p70S6K and 
p70S6K in myotubes treated with rapamycin (30μM, 1h) or vehicle. Different from untreated 
cells of the same genotype: ##P<0.01; different for the same conditions of treatment: **P<0.01; 
***P<0.001. 
Figure 4: MyrAkt induced cell hypertrophy in WT but not in AMPKα1-/-α2-/- myotubes 
(A) Size of WT and AMPKα1-/-α2-/- myotubes transduced with AdGFP and AdMyrAkt (75 
m.o.i.). Results are presented as a percentage of WT muscle cells transduced with AdGFP. 
(B) Frequency distribution of size of WT and AMPKα1-/-α2-/- myotubes transduced with 
AdGFP and AdMyrAkt. (C) Western blot of P-p70S6K and total p70S6K. Results are 
represented as means ± SEM. Different from WT cells infected with AdGFP : #P<0.05; 
##P<0.01. 
Figure 5: Increased fiber size in soleus muscle lacking AMPKα1 and α2. (A) AMPKα1, 
AMPKα2, p70S6K Thr389, p70S6K, rpS6 Ser235/236 and rpS6 expression in soleus muscle from 
AMPKα1+/+α2+/+Cre+ and AMPKα1-/-α2fl/flCre+ mice. (B) Mass of soleus muscle from 
AMPKα1+/+α2+/+Cre+ and AMPKα1-/-α2fl/flCre+ mice. Results are represented as means ± 
SEM (n=6). (C) Representative bright-field images of soleus muscle fibers from 
AMPKα1+/+α2+/+Cre+ and AMPKα1-/-α2fl/flCre+ mice. (D). Frequency distribution of cross 
sectional area fibers in soleus muscle from AMPKα1+/+α2+/+Cre+ and AMPKα1-/-α2fl/flCre+ 
mice (n=6). The fiber cross-sectional area of fibers (n=417 in mean) was determined from 
different muscle areas of 6 muscles in each group. Different from WT: *P<0.05; **P<0.01. 
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